AbbVie vs. CVS Health: Which Healthcare Stock Is a Better Buy in 2026?

AbbVie leverages a strong specialty drug portfolio to offset the loss of exclusivity for its former top-selling products.

CVS Health continues to expand its integrated healthcare model through its massive insurance and pharmacy network.

Which healthcare stock deserves a spot in your portfolio in 2026?

Investors often weigh high-margin drug developers against massive healthcare service providers when building a portfolio. Choosing between AbbVie (NYSE:ABBV) and CVS Health (NYSE:CVS) requires balancing biotech growth against retail stability.

AbbVie focuses on discovering and commercializing advanced therapies, while CVS Health operates an integrated model spanning insurance, pharmacies, and primary care clinics. Both companies play critical roles in the healthcare sector but offer very different risk and reward profiles for retail investors seeking long-term exposure in the current market.

AbbVie operates as a global biopharmaceutical giant among healthcare stocks , selling advanced therapies to wholesale distributors and government agencies. Its primary customers include McKesson , Cardinal Health , and Cencora , which represent nearly all U.S. sales. Customer concentration like this adds a layer of risk to the business. The company recently moved to strengthen its pipeline by announcing a $10.9 billion acquisition of Apogee Therapeutics in June 2026.

In FY 2025, revenue reached nearly $61.2 billion, which was an increase of roughly 8.6% compared to the prior year. Net income for the period was close to $4.2 billion, reflecting a net margin of approximately 6.9%. While revenue grew, the net margin saw a slight decline from the 7.6% reported in the previous fiscal year. Net margin is a simple way to measure how much of every dollar in sales a company keeps as profit.

As of its December 2025 balance sheet, the debt-to-equity ratio was -21.1x. This negative figure indicates that total liabilities exceed shareholder equity. The current ratio, which measures a company's ability to pay short-term debts with short-term assets, was close to 0.7x. Free cash flow for FY 2025 was nearly $17.8 billion. Free cash flow is the cash left over after a company pays for its operations and equipment.